Relation Between Protein 13 and Gestational Hypertensive Disorder

Benha University

Status: Completed

Conditions: Gestational Hypertension

Treatments: Diagnostic Test: Estimation of Protein 13

Study type: Observational

Funder types: Other

Identifiers

NCT05517512

Rc5.6.2022

Details and patient eligibility

About

the attendants of the clinic with a one-missed period (T0) underwent determination of baseline blood pressure (BP) measures and gave blood samples for estimation of levels of placental growth factor (PLGF), soluble fms-like tyrosine kinase-1 (sFlt-1) and pregnancy protein 13 (PP13). The same evaluation was repeated on the 6th, 24th, 32nd, and 36th gestational week (GW). Twenty non-pregnant women gave samples as a negative control group.

Enrollment: 138 patients

Sex: Female

Ages: 21 to 33 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Normotensive women who attended the clinic with a one-missed period (T0)

Exclusion criteria

• History of essential hypertension (HTN)
• renal diseases
• hepatic diseases
• cardiac diseases
• metabolic syndrome
• body mass index (BMI) >35 kg/ m2
• congenital heart diseases

Trial design

138 participants in 3 patient groups

Gestational Hypertension

Treatment:

Diagnostic Test: Estimation of Protein 13

Pre Eclampsia

Treatment:

Diagnostic Test: Estimation of Protein 13

Control

Treatment:

Diagnostic Test: Estimation of Protein 13